Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
- Registration Number
- NCT06259669
- Lead Sponsor
- Incyte Corporation
- Brief Summary
This observational (enrollment into the registry while the pregnancy is ongoing) study is being conducted to compare the frequency of major congenital malformation (MCM)s among infants of women exposed to ruxolitinib cream during pregnancy with infants of women not exposed to ruxolitinib cream during pregnancy.
- Detailed Description
This study is an exposure cohort study of women within the US with AD who were exposed to ruxolitinib cream at any time during their pregnancy period, defined as up to 24 days prior to the estimated date of conception (DOC) through the end of pregnancy, compared with women in the US with Atopic Dermatitis (AD) not exposed to ruxolitinib cream during pregnancy. The DOC is estimated to occur 14 days after the last menstrual period (LMP). Eligible pregnant women may self-enroll or voluntarily be enrolled by their health care provider (HCP) by calling Syneos Health. Enrollment should occur as early in pregnancy as possible.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 958
-
Women, aged 15 to 50 years, with confirmed diagnosis of mild to moderate AD.
-
Ability to comprehend and willingness to give informed consent for the study; a legal minor needs parental or legally authorized representative's consent.
-
Prospective enrollment (ie, enrollment into the registry while the pregnancy is ongoing) or retrospective enrollment (ie, enrollment into the registry within 12 months of pregnancy outcome).
-
Information available to confirm eligibility for either the exposed to ruxolitinib cream cohort or the not exposed to ruxolitinib cream cohort.
- Ruxolitinib cream cohort: consisting of pregnancies in women with AD and exposure to at least 1 application of ruxolitinib cream during the pregnancy period.
- Nonexposed cohort: consisting of pregnancies in women with AD but not exposed to ruxolitinib cream during the pregnancy period
-
Reporter (eg, participant, maternal HCP) contact information available to allow for follow-up.
-
Permission to contact the participant's and her infant's HCPs.
- If no longer pregnant and pregnancy outcome occurred more than 12 months prior to enrollment.
- Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before enrollment with another investigational medication or current enrollment in another investigational drug study.
- Any pregnancy that is exposed to any other JAK inhibitor from 5 half-lives for the specific JAK inhibitor used from LMP through the end of the first trimester for MCMs or end of pregnancy for other outcomes.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Infants of women exposed to ruxolitinib cream during pregnancy Ruxolitinib Cream - Infants of women not exposed to ruxolitinib cream during pregnancy Ruxolitinib Cream -
- Primary Outcome Measures
Name Time Method Number of major congenital malformation (MCM)s Up to 12 months after birth Defined as any major structural or chromosomal defect in live-born infants, stillbirths or spontaneous losses equal to or greater than 20 weeks' gestation, or electively terminated pregnancies of any gestational age.
- Secondary Outcome Measures
Name Time Method Number of minor congenital malformations Up to 12 months after birth Defined as abnormalities that do not significantly affect health and development, and normal variants are ascertained only among those who also have a major defect.
Number of Pregnancy outcomes Up to birth Number of live births, still births, recognized spontaneous abortions and number of elective terminations as defined in the protocol.
Adverse pregnancy outcomes Up to birth Number of preterm births and maternal pregnancy complications as defined in the protocol.
Gestational Age At time of delivery Infant Gestational Age at birth as recorded in medical records.
Infant Head Circumference Through 12 months after birth Infant Head Circumference as recorded in medical records.
Infant Sex At time of delivery Infant Sex at birth as recorded in the medical records.
Infant Body Weight Through 12 months after birth Infant Body Weight as recorded in medical records.
Number of small for gestational age (SGA)s At time of delivery Defined as a birthweight at or below the 10th percentile for a given gestational age.
Abnormal development Through 12 months after birth Based on Centers for Disease Control and Prevention (CDC) developmental milestones.
Infant Body Length Through 12 months after birth Infant Body Length as recorded in medical records.
APGAR Score At time of delivery One and five minute APGAR Scores at birth as recorded in medical records.
Trial Locations
- Locations (1)
Syneos Health (remote site)
🇺🇸Morrisville, North Carolina, United States